Globus Medical, Inc. $GMED Holdings Lowered by First Trust Advisors LP

First Trust Advisors LP decreased its stake in Globus Medical, Inc. (NYSE:GMED) by 13.0% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 299,924 shares of the medical device company’s stock after selling 44,655 shares during the quarter. First Trust Advisors LP’s holdings in Globus Medical were worth $25,841,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of GMED. PNC Financial Services Group Inc. grew its stake in Globus Medical by 12.5% during the 1st quarter. PNC Financial Services Group Inc. now owns 13,134 shares of the medical device company’s stock valued at $1,132,000 after acquiring an additional 1,455 shares in the last quarter. Convergence Investment Partners LLC acquired a new stake in shares of Globus Medical during the first quarter worth approximately $2,165,000. WCM Investment Management LLC acquired a new stake in shares of Globus Medical during the first quarter worth approximately $16,965,000. Dimensional Fund Advisors LP grew its position in Globus Medical by 2.0% during the first quarter. Dimensional Fund Advisors LP now owns 1,769,897 shares of the medical device company’s stock valued at $152,474,000 after purchasing an additional 33,976 shares in the last quarter. Finally, Parallel Advisors LLC increased its stake in Globus Medical by 63.3% in the 1st quarter. Parallel Advisors LLC now owns 1,778 shares of the medical device company’s stock valued at $153,000 after buying an additional 689 shares during the period. Hedge funds and other institutional investors own 95.16% of the company’s stock.

Globus Medical Stock Up 2.9%

GMED stock opened at $80.49 on Wednesday. The company has a market capitalization of $10.93 billion, a price-to-earnings ratio of 18.72, a P/E/G ratio of 1.62 and a beta of 0.95. Globus Medical, Inc. has a 12 month low of $51.79 and a 12 month high of $101.40. The firm has a 50 day moving average of $79.79 and a two-hundred day moving average of $85.85.

Globus Medical (NYSE:GMED) last announced its quarterly earnings results on Thursday, May 7th. The medical device company reported $1.12 EPS for the quarter, topping the consensus estimate of $0.92 by $0.20. Globus Medical had a net margin of 18.92% and a return on equity of 13.46%. The company had revenue of $759.85 million for the quarter, compared to analyst estimates of $740.35 million. During the same quarter in the prior year, the business posted $0.68 EPS. Globus Medical’s quarterly revenue was up 27.0% on a year-over-year basis. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. On average, research analysts expect that Globus Medical, Inc. will post 4.74 EPS for the current fiscal year.

Insider Buying and Selling

In other Globus Medical news, Director David D. Davidar sold 25,000 shares of the firm’s stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $80.76, for a total transaction of $2,019,000.00. Following the transaction, the director directly owned 510,175 shares in the company, valued at $41,201,733. This trade represents a 4.67% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 18.38% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

GMED has been the topic of several research analyst reports. Truist Financial lowered their price target on shares of Globus Medical from $115.00 to $100.00 and set a “buy” rating on the stock in a report on Thursday, July 16th. Weiss Ratings reissued a “hold (c+)” rating on shares of Globus Medical in a research report on Monday, July 13th. Needham & Company LLC boosted their target price on Globus Medical from $114.00 to $117.00 and gave the company a “buy” rating in a research note on Friday, May 8th. Wells Fargo & Company dropped their target price on Globus Medical from $104.00 to $103.00 and set an “overweight” rating on the stock in a research report on Friday, May 8th. Finally, Royal Bank Of Canada dropped their target price on Globus Medical from $120.00 to $115.00 and set an “outperform” rating on the stock in a research report on Monday, July 13th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $102.08.

Globus Medical Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.